Amneal Closes Deal to Acquire Generic Business of Actavis Australia / by TI

MELBOURNE and  SYDNEY,  Australia, Amneal  Pharmaceuticals  Pty  Ltd  and Actavis Australia Pty Ltd, a subsidiary of Actavis plc (NYSE: ACT),today announced that Amneal has  completed  the  acquisition  of  substantially all  of  Actavis’ in-country  generic  pharmaceuticals business.Financial terms of the agreement were not disclosed. Under the terms of the agreement, Amneal shall have the right to distribute Actavis-labeled product on a transitional basis. Both companies will work together to transition suppliers and customers and to minimize disruption to the ongoing business.  

About Amneal Pharmaceuticals LLC Amneal Pharmaceuticals LLC is a global supplier of generic pharmaceuticals, vertically-integrated across the entire supply chain from R&D to finished goods. Since its inception in 2002, Amneal has invested  extensively  in  R&D  resources,  manufacturing  infrastructure,  and  strategic  expansion opportunities—all   contributing   to   its   significant   growth.   The   Company   prides   itself   on   its unwavering  commitment  to  quality,  strong  business  relationships,  and  innovative  approach  to maximizing value. Amneal is privately-held with U.S. headquarters in Bridge water, New Jersey and international    headquarters    in    Zug,    Switzerland.    For    more    information,    please    visit About Actavis Actavis plc (NYSE: ACT), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model –Growth Pharma.  Actavis is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world.  Actavis markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women’s health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world’s third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Actavis is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry and a leading position in the submission of generic product applications globally. With commercial operations in approximately 100 countries, Actavis is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives. Actavis intends to adopt a new global name –Allergen –pending shareholder approval in 2015. For more information, visit Actavis' website at